Native Hawaiian health focus of graduating JABSOM PhD – UH System Current News

Christian Dye

A graduate student in the University of Hawaii at Mnoa John A. Burns School of Medicine (JABSOM) is conducting research that may have a significant impact on underserved and vulnerable populations. Christian Dye is probing the causes of diabetes and other chronic diseases prevalent in Native Hawaiian and other communities.

Dye, currently a faculty member at JABSOM, will earn his PhD from UH Mnoa in spring 2020.

My current research seeks to understand inflammation-associated disorders, like diabetes, from an epigenetics viewpointthe influence of environmental factors (diet, exercise, smoking, etc.) on how our cells function by influencing how genes are turned on, off, or even changed, he explained.

JABSOM has allowed me to be at the center of research that is not only meaningful, but was instrumental in allowing me to do so in the communities that I feel most passionate about, Native Hawaiians and Pacific Islanders, Dye said.

Dye focuses on epigenetics to determine the potential mechanisms underlying disease pathogenesis. We may be able to understand whether certain areas of the genome are epigenetically regulated and if such regulation may be involved in how immune cells function and whether this leads to immune dysfunction or inflammation.

Exciting results of Dyes research include the benefits of an intervention in Native Hawaiians with diabetes, which led to drastic changes in epigenetic profiles. The epigenetic alterations were linked to changes in gene expression and immune cell function (reduced inflammation) that were associated with better glycemic control. These findings have potentially bridged cell function and beneficial health outcomes with epigenetic modifications that may regulate genes enriched in biological functions important to immune cells, he said.

Dye plans to develop a network of community-based participatory research centers for investigation of cellular, molecular or biological mechanisms that may underlie the benefits of culturally-based practices and interventions. By bridging indigenous knowledge and practice within a western context of science, technology and medicine, we may be able to understand the science as to why these practices are beneficial to at-risk communities while also elucidating how certain cells, like immune cells, may function, and the potential that their regulation may be involved in beneficial health outcomes which can eventually be used in targeted strategies for understanding disease risk and possible therapeutics.

Dyes interest in the cellular and molecular biology of health disparities motivated him to work at the UH medical school. JABSOM has allowed me to be at the center of research that is not only meaningful, but was instrumental in allowing me to do so in the communities that I feel most passionate about, Native Hawaiians and Pacific Islanders, he said. JABSOM also allowed me to enter some of the communities where these health disparities are prevalent and use research to help understand them.

Read more on the JABSOM website.

See the original post:

Native Hawaiian health focus of graduating JABSOM PhD - UH System Current News

DTR’s news round-up 2019: the stories that defined the year – Drug Target Review

Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.

Drug Target Review has published a wide range of news stories this year, from the identification of novel drug targets to improvements in toxicology studies and developments in screening.

As the year draws to a close, we reflect on the biggest and most popular stories from 2019. To read the full pieces, click on the title of each news story.

A genetic analysis study revealed that variants of hundreds of genes work together in contributing to the development of Tourettes syndrome, in our tenth most popular story this year.

According to the researchers, from the Massachusetts General Hospital (MGH) and collaborators, their findings confirm that the underlying basis for Tourettes syndrome is polygenic, meaning that hundreds of small DNA changes cause the condition, rather than one inactive gene.

The scientists said their next step is to expand their sample size to around 12,000 patients, made possible with a potential international collaboration.

The study was published in the American Journal of Psychiatry.

A group of researchers identified new genetic targets on which BRCA2-driven cancer cells are dependent upon, providing a potential avenue for drug development.

The study, conducted at Brigham and Womens Hospital, used CRISPR and short-hairpin RNAs (shRNAs) to test 380 genes with a known or suspected role in DNA-damage response. This allowed the team to narrow in on the most promising genes: APEX2 and FEN1, two novel targets for breast cancer.

The results were published in Molecular Cell.

Immunotherapy treatment could reduce the persistence of HIV in patients receiving triple therapy, found a group of researchers.

The researchers, from the University of Montreal Hospital Research Centre, discovered that these therapies expose the virus to the immune system. Three proteins PD-1, LAG-3 and TIGIT were uncovered by the scientists as frequently expressed on the surface of HIV-hiding cells; these proteins are also cancer targets.

According to the team, their study could lead to the development of new HIV therapies based on cancer immunotherapies.

The study was published in Nature Communications.

Researchers at the Indiana University School of Medicine developed a blood test to measure pain and improve diagnosis. The team analysed hundreds of patient samples to reveal biomarkers in their blood, which could be used as a scale to determine pain.

According to the researchers, the biomarkers act like a signature that can be matched against a prescription database. This could allow medical professionals to select the appropriate compound and reduce pain for the patient.

The study was published in Molecular Psychiatry.

A team of scientists revealed that immune cells could be key in causing endometriosis, a pelvic pain experienced by women, through an investigation into macrophages. The study was led by researchers from Warwick Medical School and the University of Warwick.

Macrophages can adapt their function according to local signals from their surroundings and so become modified by disease. This led the researchers to add modified macrophages to a cell culture, which resulted in the production of higher levels of insulin-like growth factor-1 (IGF-1).

The team conclude that macrophages therefore present a drug target for endometriosis.

The results can be found in The FASEB Journal.

Scientists from the University of Pennsylvania imaged a molecule that induces inflammation and leads to lupus, in our fifth most popular story of 2019. The researchers discovered that the molecule is comprised of two sections: SHMT2 and BRISC, a cluster of proteins. When these two sections bind to each other, they cause inflammation.

When mice models lacking BRISC were tested, they were resistant to lupus. This led the team to conclude that a molecule which blocks BRISC and SHMT2 could be a drug target for lupus.

The findings were published in Nature.

A team of researchers reported that a CRISPR-Cas9 gene therapy which specifically reduces fat tissue and obesity-related metabolic disease was successful in mice.

The scientists, from Hanyang University, argue that their technique could be used as a way to combat type 2 diabetes and other obesity-related diseases.

Targeting Fabp4, a fatty acid metabolism gene, the researchers observed a 20 percent reduction of body weight in obese mice. It also resulted in improved insulin resistance after only six weeks of treatment.

The findings were published in Genome Research.

A compound that promotes the rebuilding of the protective sheath around nerve cells has been developed by researchers at the Oregon Health & Science University (OHSU).

The team found that the S3 compound reverses the effect of hyaluronic acid (HA) in mice. HA has been found to accumulate in the brain of patients with multiple sclerosis, and accumulation of HA

has also been linked to maturity failure of cells called oligodendrocytes, which generate myelin, the protective layer of axons.

The team therefore believe that the S3 compound could provide a therapeutic strategy for treating nervous system disorders.

The study can be found in Glia.

A group of researchers formed a complex view of the functional dysbiosis in the gut microbiome during inflammatory bowel disease (IBD), to reveal new targets for treatments.

The scientists, from theBroad InstituteofMITandHarvard University, observed microbial changes and human gene regulatory shifts from stool and blood samples of patients.

This multi-omic study enabled the team to discover that during periods of disease activity, IBD patients had higher levels of polyunsaturated fatty acids in both the blood and stool. They also identified other varying levels of nutrients and vitamins, presenting several potential drug targets.

The findings were published in Nature.

In our most popular news piece this year, researchers found that the small molecule PJ34 reduces the number of human pancreatic cancer cells in transplanted tumours by 90 percent.

The team, from Tel Aviv University, built on previous research to treat xenografts with their small molecule. It is permeable in the cell membrane, but affects human cancer cells exclusively, making it an attractive compound for development.

The scientists found that PJ34 causes a rapid cell death and in one mouse, the tumour completely disappeared. They concluded that the molecule could be a potent therapeutic against pancreatic cancer.

The results were published in Oncotarget.

Related organisationsBrigham and Women's Hospital, Hanyang University, Harvard University, Indiana University School of Medicine, Massachusetts General Hospital (MGH), MIT, Oregon Health & Science University (OHSU), Pennsylvania University, Tel Aviv University, University of Montreal Hospital Research Centre, Warwick Medical School, Warwick University

The rest is here:

DTR's news round-up 2019: the stories that defined the year - Drug Target Review

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors – BioSpace

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointment of Wendy L. Yarno as a Director of its Board of Directors.

Ms. Yarno spent 26 years at Merck & Co. in commercial and human resource positions of increasing seniority, including most recently as Executive Vice President and Chief Marketing Officer. She previously served as General Manager, Cardiovascular / Metabolic U.S. Business Unit and as Executive Vice President, Worldwide Human Health Marketing. In these roles, Ms. Yarno developed deep expertise in pharmaceutical commercialization, including drug development, regulatory strategy, market development, global product strategy and product life-cycle management.

Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Global Blood Therapeutics, Inovio Pharmaceuticals, Inc. and Myokardia. She previously served on the board of directors of various other life science companies, including Alder Biopharmaceuticals, Durata Therapeutics, St. Jude Medical and Medivation.

"Wendy brings a unique breadth of experience in pre-and post-launch commercialization of pharmaceuticals to our Board," said John Diekman, Ph.D., Chairman of IDEAYA's Board of Directors.

Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences observed that "Wendy's commercial experience and leadership will be invaluable to IDEAYA, in particular as we advance clinical development of our lead clinical development program, IDE196, into a potentially registration-enabling single-arm Phase 2 clinical trial in metastatic uveal melanoma, anticipated in first quarter 2020."

"I'm delighted to join IDEAYA's Board of Directors to help advance IDEAYA's vision of improving lives through transformative precision medicines. I am excited to contribute to IDEAYA's pipeline of precision medicine oncology therapeutics, including approaches directly targeting oncogenic pathways and synthetic lethality an emerging class of precision medicine targets," said Ms. Yarno.

About IDEAYA BiosciencesIDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.

Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to expected timing for advancing clinical development of IDE196 into a potentially registration-enabling single-arm Phase 2 clinical trial in metastatic uveal melanoma. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 13, 2019 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-wendy-yarno-to-its-board-of-directors-300976587.html

SOURCE IDEAYA Biosciences, Inc.

Company Codes: NASDAQ-NMS:IDYA

See original here:

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors - BioSpace

Graduating with a master’s degree AND a medical discovery – Science at ANU

For her masters degree in biotechnology, Pallavi Venkatesh didnt just learn about the latest advances in medical science, she made some too.

Pallavi studied one of the most important tools in modern medicine, the Vaccinia virus, which was used as a vaccine to eradicate smallpox.

I found out that different strains of the virus preference different pathogen-sensing molecules found within immune cells, which is really exciting, she says.

Better understanding how different virus strains are detected by immune cells could help fine-tune its use as a tool against cancers and other viruses in the future.

Our finding was exciting as we found that more than one of these pathogen sensor molecules was involved and that different strains may activate different sensor molecules preferentially.

Pallavi says the coursework components of her Master of Biotechnology (Advanced) at The Australian National University (ANU) gave her the skills she needed to undertake this original research.

I studied genomic sciences, molecular biology and cell biology, which I really enjoyed, she says.

For the research component of her degree, she had the opportunity to be part of an innovative team at The John Curtin School of Medical Research (JCSMR).

I did my research under David Tscharke in the Immunology Department, she says.

Working with David was an amazing learning opportunity, he pushes you to be the best you can and provides incredible support.

I also received additional support from members of the lab which helped me through my research year.

Prior to arriving at ANU, Pallavi completed her undergraduate degree at Jyoti Nivas College in Bangalore.

She says that Canberra and living on campus at Toad Hall provided the ideal environment for a postgraduate scholar.

I highly recommend ANU as a place to study, she says. I made lots of new friends here, friends for life.

Inspired by her time at JCSMR, Pallavi is now planning to pursue a career in immunology.

Find out more about how a Master of Biotechnology at ANU can help launch your career in medical, biological or agricultural science.

Continue reading here:

Graduating with a master's degree AND a medical discovery - Science at ANU

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases – GlobeNewswire

SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and other types of organ damage, today announced it dosed the first participant in a Phase 1 clinical trial evaluating ANG-3070 in healthy volunteers. ANG-3070 is an orally bioavailable small molecule intended for development as a potential treatment for idiopathic pulmonary fibrosis, primary focal segmental glomerulosclerosis (FSGS) and a variety of other fibrotic diseases.

We are pleased to announce the first participant dosed in this Phase 1 healthy volunteer trial investigating the safety and tolerability of ANG-3070. Entering the clinic is an important milestone for ANG-3070, our precision drug candidate, which has already demonstrated in vivo proof-of-concept in a variety of animal models as an anti-fibrotic agent, said Jay Venkatesan, M.D., Chief Executive Officer. This is an important step in establishing the safety profile of a potential treatment for a variety of fibrotic diseases proven difficult to treat or for which there are no approved therapies.

This Phase 1 randomized, double-blind, placebo-controlled study will primarily assess the safety, tolerability, pharmacokinetics and food effect of ANG-3070 in healthy adult subjects. Angion expects this Phase 1 healthy volunteer trial to complete enrollment in the first half of 2020 and anticipates presenting full data at scientific meetings after trial completion.

About ANG-3070ANG-3070 is an orally bioavailable small molecule fibrokinase inhibitor under development for the treatment of chronic fibrotic diseases. ANG-3070 has exhibited preferential activity against molecular pathways involved in and associated with poor outcomes of pulmonary and renal fibrosis. ANG-3070 is currently being developed as a precision medicine guided therapy for pulmonary fibrosis and primary focal segmental glomerulosclerosis.

About Angion Biomedica Corp.Angion Biomedica Corp. is a clinical stage biopharmaceutical company focused on developing novel therapeutics for serious, life-threatening conditions without adequate therapeutic options. The Companys lead clinical asset, ANG-3777, is engineered to activate the HGF/c-Met pathway, an important mechanism in organ repair. Enrollment is ongoing in a placebo-controlled Phase 3 trial examining the efficacy of ANG-3777 in reducing the severity of delayed graft function after kidney transplant. Angion is also developing ANG-3070, an oral small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach. For further information, please visit http://www.angion.com.

Media ContactCherilyn Cecchini, M.D.LifeSci Public Relations646-876-5196ccecchini@lifescipublicrelations.com

Originally posted here:

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases - GlobeNewswire

Triple Negative Breast Cancer Recurrence Prediction Method Developed – Clinical OMICs News

Triple negative breast cancer is one of the most difficult types of breast cancer to treat, due to the mechanism being undefined. It is negative for the three most commonly mutated breast cancer markers: HER2, estrogen receptors, and progesterone receptors. It is one of the most aggressive and deadliest types of breast cancer because it lacks common traits used to diagnose and treat most other breast cancers. This lack of definition also makes it difficult to predict the outcome of treatment.

However, researchers at Indiana University have developed a new bioassay that can better predict triple negative breast cancer outcomes, particularly the likelihood cancer recurrence and survival.

Milan Radovich, Ph.D., and Bryan Schneider, M.D., discovered that of women whose blood plasma contained genetic material from a tumor (circulating tumor DNA known as ctDNA), 56% were likely to be cancer-free two years following chemotherapy and surgery. Patients who did not have ctDNA in their plasma had an 81% likelihood to not have cancer return after the same amount of time. The researchers recently presented their findings at the San Antonio Breast Cancer Symposium.

This study, a part ofIndiana Universitys Precision Health Initiative Grand Challenge for triple negative breast cancer, also examined the impact of circulating tumor cells (CTC), live tumor cells released from tumors into the surrounding blood and lymph, on recurrence.

What we found is if patients were negative for both ctDNA and CTC, 90% of the women with triple negative breast cancer remained cancer-free after two years, said Radovich, who is lead author of this study.

The two researchers, along with colleagues from the Hoosier Cancer Research Network, based their findings on analyzing the plasma from blood samples of 142 women with triple negative breast cancer, at stage I, II or III. These women had previously undergone chemotherapy prior to surgery, and were participants in another study testing genomically directed therapy. When doctors used FoundationOne Liquid to test for ctDNA levels, 90 of the women tested positive and the remaining 52 were negative.

Detection of ctDNA was also associated with poor overall survival. Specifically, the study showed that patients with detectable levels of ctDNA were four times more likely to die from the disease when compared to those who tested negative for ctDNA.

The authors say the next step is a new clinical study expected to begin in early 2020, which leverages this discovery to enroll patients who are at high risk of breast cancer recurrence to evaluate new treatment options for them.

Just telling a patient they are at high risk for reoccurrence isnt overly helpful unless you can act on it, said Schneider, who is senior author. Whats more important is the ability to act on that in a way to improve outcomes.

Radovich says each triple negative breast cancer case is unique. Each one has its own set of mutations that cause that cancer and drive it and its really through advances in precision medicine that were able to tailor therapy the best we can to treat these patients. Moving forward, what we know is that the technology is rapidly advancing. Our ability to detect the circulating tumor DNA is actually quite good now, but its getting better even with advances in technology.

We were able to actually look at both in this case, how ctDNA and CTCs may work together to determine which patients will relapse and which will not, said Radovich, who also said the capability to examine a patients plasma for tumor mutations has only been around for the past three years.

What I think were proud of here at IU is that were already applying this for clinical care. Were using this actively for our patients here at the IU Simon Cancer Center, as well as in clinical trials and were proud that were really providing our patients the most cutting-edge technology available on the planet.

Doctors and scientists arent the only ones who are excited by the latest breakthrough in triple negative breast cancer.

Nadia Miller, a 12-year triple negative breast cancer survivor and president of Indianapolis-based breast cancer advocacy group Pink-4-Ever, says she and the community are excited about the implications of the discovery as well.

Specifically for patients, and then just what the researchers are doing, it gives us very intentional data to use for the recovery and the survivorship of a persons life, said Miller. So I think what they are doing is just laying the foundation for years and years to come. The communitys response to this is that theyre hopeful. Theyre hopeful to see whats next and just really excited about this groundbreaking information.

She went on to say, This is a huge leap toward more favorable outcomes and interventions for triple negative breast cancer patients.


Triple Negative Breast Cancer Recurrence Prediction Method Developed - Clinical OMICs News

52 UC San Diego Researchers Are Most Highly Cited in Their Fields – UC San Diego Health

Fifty-two faculty members and researchers at the University of California San Diego are among the worlds most influential in their fields. The Web of Science Group, an information and technology provider for the global scientific research community, compiled its2019 Highly Cited Researcherslist of more than 6,000 scientists from around the world whose studies were among the top 1% of most-cited publications in their field over the past 11 years.

The number of highly cited researchers from UC San Diego increased by 13% over last years number of forty-six. The listing covers 21 fields of study as well as a cross-field category for researchers who are widely cited across multiple fields. UC San Diego had researchers listed in 14 fields, with the most cited in cross-field (23), followed by molecular biology and genetics (5), clinical medicine (4) and social sciences (4).

UC San Diego has some of the most dedicated, brilliant and hard-working faculty and researchers in the world. Their inclusion on the list of highly cited researchers is a measure of their impact in their respective fields of study as they continue to advance the frontiers of knowledge, said Chancellor Pradeep K. Khosla.

Of particular note is Director for the Center of Microbiome Innovation Rob Knights inclusion in three separate areas of study (biology and biochemistry, environment and ecology, microbiology). Out of 6,216 highly cited researchers, only 11 were cited in three fields, making Knight part of a super elite 0.3% of those listed.

There were also 23 Nobel laureates on the list, one of whom, Roger Tsien, was a distinguished professor of both Pharmacology in the School of Medicine and of Chemistry and Biochemistry at UC San Diego until his death in 2016. He shared the Nobel Prize in Chemistry with two others in 2008 for discovering and developing green fluorescent protein.

David Pendlebury, Senior Citation Analyst at the Web of Science Groups Institute for Scientific Information said that the highly cited researchers create gains for society, innovation and knowledge that make the world healthier, richer, more sustainable and more secure.

It is especially encouraging to see not only the number of highly cited researchers at the university, but the broad range of fields in which they are cited. It really speaks to the fact that UC San Diego conducts groundbreaking research across a wide range of disciplines, said Vice Chancellor for Research Sandra A. Brown. I congratulate everyone on their excellent research and contributions.

The 52 UC San Diego faculty members named by Web of Science and the fields of study in which they were cited are:

Gregory Aarons,social sciences

Ludmil Alexandrov, molecular biology and genetics

David Brenner,cross-field

Kristin Cadenhead,psychiatry/psychology

Kelli Cain, social sciences

Shu Chien, cross-field

Don Cleveland,neuroscience and behavior

Seth Cohen,chemistry

Pieter Dorrestein,cross-field

Mark Ellisman, cross-field

Mark Estelle,plant and animal science

Michael Folger, cross-field

Anthony Gamst, cross-field

Christopher Glass,molecular biology and genetics

Uri Gneezy,economics and business

Antonio Gonzalez, microbiology

Kun-Liang Guan,molecular biology and genetics

Trey Ideker,cross-field

Michael Karin,molecular biology and genetics

Arthur Kavanaugh,clinical medicine

Dusan Keres, space science

Rob Knight,(listed in 3 fields) biology and biochemistry, environment and ecology, microbiology

Razelle Kurzrock, clinical medicine

Lisa Levin, cross-field

Irene Litvan, neuroscience and behavior

Rohit Loomba, clinical medicine

Prashant Mali, biology and biochemistry

Eliezer Masliah, cross-field

Victor Nizet, cross-field

Jerrold Olefsky,cross-field

Bernhard Palsson,biology and biochemistry

Veerabhadran Ramanathan,cross-field

Bing Ren,molecular biology and genetics

Jeremy Rich, cross-field

Douglas Richman,cross-field

Michael Sailor,cross-field

James Sallis,social sciences

William Sandborn,clinical medicine

Bernd Schnabl, cross-field

Julian Schroeder,plant and animal science

Terrence Sejnowski, cross-field

Claude Sirlin, cross-field

Murray Stein,psychiatry/psychology

Steffanie Strathdee, cross-field

Roger Tsien, cross-field

Ming Tsuang,psychiatry/psychology

Joseph Wang,chemistry

Shang-Ping Xie,geosciences

Gene Yeo, cross-field

Kun Zhang, cross-field

Liangfang Zhang,cross-field

Yunde Zhao, plant and animal science

Shu-Hong Zhu, social sciences

You can read about Web of Sciences methodology on their website.

UC San Diegos Studio Ten 300 offers radio and television connections for media interviews with our faculty. For more information, email .(JavaScript must be enabled to view this email address).

See more here:

52 UC San Diego Researchers Are Most Highly Cited in Their Fields - UC San Diego Health

Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – Business Wire

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima BV and Aptima CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther system.

Vaginitis, a condition that affects millions of women every year, is responsible for up to half of all gynecologic visits in the United States, as well as significant expense to the healthcare system.1

As leaders in womens health, we delivered on the need for new, molecular assays for vaginitis that have higher sensitivity and specificity than traditional methods, said Kevin Thornal, Hologics division president, Diagnostic Solutions. This study demonstrates that our assays are better at diagnosing infection than previously available options, which ultimately will ensure women receive the right treatment sooner.

The study notes that women suffering from vaginitis are often underserved by the current paradigm of inaccurate or incomplete diagnosis guiding inadequate or inappropriate treatment. Prior to the introduction of molecular assays, clinicians had no choice but to analyze fresh vaginal discharge samples using a combination of older, subjective methods pH, a potassium hydroxide (KOH) whiff test and Gram-stained microscopic examination to identify the underlying cause.

The new Aptima molecular tests circumvent barriers to accurate diagnosis associated with the use of these traditional methods, including absence of proper equipment, lack of training, and access to microscopy in the clinic. These and other barriers can result in many women being misdiagnosed, which the study says can lead to incorrect, misguided or prolonged treatment.1 In fact, separate research shows that when treatment is based on diagnosis with these traditional methods, more than half of women with vaginitis experience recurring symptoms.2

Many women try to self-diagnose and self-treat before eventually visiting a healthcare provider, assuming that abnormal vaginal discharge, itching or irritation is due to a simple yeast infection, said the studys corresponding author, Dr. Jane R. Schwebke, professor of medicine at the University of Alabama at Birmingham. But BV or TV left untreated or improperly treated can put women at risk for a variety of complications, including an increased chance of getting sexually transmitted infections (STIs) such as chlamydia or HIV, pelvic inflammatory disease, and pregnancy-related risks including premature delivery, low birth weight and infertility.2,4 These objective and comprehensive diagnostic tests will mitigate such risks and allow clinicians to feel more confident that theyre properly treating women.

BV (bacterial vaginosis) is the most common vaginal infection in the U.S., affecting an estimated 21 million women a year.3 Together with CV (vulvovaginal candidiasis) commonly known as yeast infections and TV (trichomonas vaginalis), individually or in combination, these three vaginal infections cause about 90 percent of vaginitis infections.2,4 Each cause of vaginitis has its own characteristics, consequences and treatment recommendations, which vary between BV, CV and TV, further reinforcing the need for accurate diagnoses.

Study Details

Subjects in the multi-center, cross-sectional diagnostic accuracy study for the Aptima BV and Aptima CV/TV assays were at least 14 years old with symptoms of vaginitis such as abnormal vaginal discharge, vaginal odor, genital itching or irritation, pain or discomfort during sexual intercourse or urination, edema or erythema. They were enrolled at 21 U.S. sites, including clinical research centers and emergency medicine, family planning, public health, STI and family medicine/obstetric-gynecologic (OB-GYN) facilities between June and October 2018.

Patient- and clinician-collected vaginal swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima CV/TV assays. The prevalence of infection was similar for clinician- and patient-collected samples: 49 percent for BV, 29 percent for CV due to the Candida species group, 4 percent for CV due to C. glabrata, and 10 percent for TV. Sensitivity and specificity estimates for the tests in clinician-collected samples were, respectively, 95.0 percent and 89.6 percent for BV, 91.7 percent and 85.8 percent for the Candida species group, 84.7 percent and 99.1 percent for C. glabrata, and 96.5 percent and 98.9 percent for TV. Sensitivity and specificity were similar in patient-collected samples.

Hologic offers 16 FDA-cleared assays on the Panther system that detect more than 20 pathogens, offering the only high-throughput molecular diagnostic platform in the U.S. to combine comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system.

For more information on the Aptima BV and Aptima CV/TV assays, visit http://www.hologic.com.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving womens health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologics diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Aptima, Panther and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Source: Hologic, Inc.


Go here to see the original:

Newly Published Research Shows that Hologic's Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods - Business Wire

Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market – PRNewswire

LONDON, Nov. 25, 2019 /PRNewswire/ -- The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 70 tables and 115 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the global protein expression market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/#download_sampe_div

Report Scope

Global Protein Expression Market forecaststo 2029

Global Protein Expression Market forecaststo 2029by Expression System: Cell-free Expression System Prokaryotic/ Bacterial Expression System Yeast Cell Expression Systems Algal-based Expression Systems Insect Cell Expression Systems Mammalian Cell Expression Systems

Global Protein Expression Market forecasts to 2029by Product & Services: Reagents Expression Vectors Competent Cells Instruments Services

Global Protein Expression Market forecasts to 2029by Application: Therapeutic Applications Industrial Application Research Application

Global Protein Expression Market forecaststo 2029by End-User: Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations (CROs)

Global Protein Expression Market forecaststo 2029by National Market: North America: US, Canada EU: Germany, France, UK, Italy, Spain Asia: Japan, China, India

Assessment of selectedleading companies that hold major market shares in the protein expression industry: Agilent Technologies Bio-Rad Technologies EMD Milipore New England Biolabs, Inc. Oxford Expression Technologies, Ltd. Promega Corporation Qiagen NV Takara Bio, Inc. Thermo Fisher Scientific, Inc.

Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the protein expression market. Moreover, this report discussesfactors that drive and restrain the protein expression market.

Key Questions Answered by This Report: What is the current size of the protein expression market? How much will this market be worth from 2019-2029? What will be the main drivers and restraints for this market? What are the different segments of the protein expression market? How much will each of these segments be worth during 2019-2029 and how will their market shares change during this period? What are the largest national protein expression markets? How much will these markets be worth from 2019-2029? How will the emerging markets affect the market shares of the mature markets? What are the most prominent companies in the market? What products and services do they offer, and what are the main features and advantages of them? What are the main trends affecting the market? What technologies will increase in prominence between 2019 and 2029? What are the advantages of these technologies? What are the main strengths, weaknesses, opportunities and threats for the market? What are the social, technological, economic and political factors affecting the market?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Abgenex Agilent Technologies Inc.Anthem BiosciencesAstraZenecaBayerBio-Rad TechnologiesBiotechnology Industry Research Assistance Council BioTek InstrumentsBrammer BioBristol-Myers Squibb Cancer Research UK Centers for Disease Control and Prevention Clontech Laboratories, Inc. Department of Biotechnology EMD MilliporeGIMDx, Inc. HD Biosciences Co., Ltd.Icagen, Inc. IncellDx, IncInnoCore PharmaceuticalsInSphero AG Institute for Molecular Medicine Finland JanssenLabcyte Inc.LikardaLuxcel Biosciences LtdMerckMerck & Co., IncNew England Biolabs Inc.Novo Nordisk Foundation Center for Biosustainability On Target Co., Ltd. OriGeneOxford Expression Technologies LtdPharmaceutical Research and Manufacturers of America Promega CorporationQiagen NVSanofiSciGenomSigma-Aldrich CorporationSino BiologicalsTakara Bio Inc.Takeda Pharmaceutical Company Technical University of Denmark Thermo Fisher Scientific Inc.UCBWaferGen Bio-systems, Inc. World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029

Pharmaceutical Contract Manufacturing Market 2019-2029

Global Medical Device Contract Manufacturing Market Forecast 2019-2029

3D Printing for Healthcare Market Report 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

SOURCE Visiongain


Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market - PRNewswire

New Immune-Boosting Pet Supplement May Add Years to the Life of Your Pet – PRNewswire

VENTURA, Calif., Nov. 22, 2019 /PRNewswire/ --A California-based pet wellness company has launched a new natural health supplement formulated to boost your pet's immune system and protect dogs and cats against cancer and other life-threatening diseases.

"Cancer is the number-one killer of dogs and cats," explains VetSmart Formulas founder and CEO, Russ Kamalski. "We wanted to create a product that would help pets stay healthy and active for years to come. That's why we've spent the past few years perfecting the formula and making sure it includes active ingredients that have been proven to promote normal cell growth and support long-term health in pets."

The supplement's main ingredients are four medicinal mushrooms from Asia that have been proven to inhibit the growth of cancerous tumors, strengthen the immune system, lower cholesterol levels and blood pressure, and reduce inflammation. The product also includes a patented white turmeric extract that contains active ingredients that have been shown to protect against neurodegenerative diseases, arthritis, cardiovascular risks, and liver damage.

Kamalski says that the powerful combination of natural ingredients is one of the most effective antioxidant supplements for pets and is designed to strengthen the immune system for both young pets as a preventative measure, and for those dogs and cats struggling with diseases such as cancer, it helps the pet's natural immune defenses in an extraordinary way.

"It is the responsibility of the pet owner to do everything possible to minimize the risk of cancer in their pets. That includes a sensible lifestyle with sufficient exercise, weight management, drinking clean water, healthy food intake, and avoiding toxins," says Doctor of Veterinary Medicine Shawn Messonnier, founder of Paws & Claws Animal Hospital in Plano, Texas. "Giving your pets a high-quality antioxidant supplement is highly recommended to further reduce the risk of cancer."

Kamalski, who has decades of experience in the natural health supplement industry, decided to develop this all-natural supplement when his 12-year-old dog, Sienna, developed bone cancer. The doctors gave her just a few months to live but Kamalski exhaustively researched alternative cancer treatments and developed an early prototype of the Critical Immune Defense formula to aid in her treatment and recovery. With the support of Sienna's veterinarian and oncologist, he succeeded in extending Sienna's life by almost two years.

"The oncologists who were treating her were amazed," Kamalski says. "Her tumors basically stopped growing and started to shrink. Not only did the product help slow the cancer growth, her quality of life dramatically improved. They'd never seen anything like it."

Critical Immune Defense is not available in retail stores and can be found at the Pet Wellness Direct Website: http://getvsf.com/cid-press

About VetSmart Formulas:VetSmart Formulas is a line of high-quality pet supplements sold directly to consumers by Pet Wellness Direct, an online pet wellness company founded in 2015. The company's all-natural products are made in the USA in FDA audited labs, have no artificial ingredients or flavors, are wheat-free, and are based on scientifically superior formulas that pet professionals demand. The company's board of advisors includes a professor of biochemistry and molecular medicine and four veterinarians who are passionate about protecting our pets from disease and increasing pet health and longevity.

Related Links:

Russ KamalskiCEOPet Wellness Direct888-212-8400, ext. 802inquiries@petwellnessdirect.com

This release was issued through WebWire. For more information visit http://www.webwire.com.

SOURCE Pet Wellness Direct

Originally posted here:

New Immune-Boosting Pet Supplement May Add Years to the Life of Your Pet - PRNewswire

The nature of salmonella is changing and it’s meaner – MSUToday

Salmonella is acting up in Michigan, and it could be a model for whats happening in other states, according to a new Michigan State University study.

The study, appearing in Frontiers in Medicine, documents a substantial uptick in antibiotic resistant strains, and consequently, longer hospital stays as doctors work to treat the increasing virulent pathogens.

If you get a salmonella infection that is resistant to antibiotics today, you are more likely to be hospitalized longer, and it will take you longer to recover, said Shannon Manning, MSU Foundation professor in theDepartment of Microbiology and Molecular Genetics and senior author of the study. We need better detection methods at the clinical level to identify resistant pathogens earlier so we can treat them with the right drugs the first time.

Losing a day or more to misdiagnosis or improper treatment allows symptoms to get worse. Doctors might kill off a subpopulation of bacteria that are susceptible, but the ones that are resistant grow stronger, she added.

Salmonella is a diverse group of bacterial pathogens that causes foodborne infections. Infected patients often develop diarrhea, nausea, vomiting and abdominal pain, though some infections are more severe and can be life threatening.

When it comes to treatments, each strain reacts differently to the range of antibiotics available for prescription by doctors. So getting it right the first time is crucial.

Specifically in Michigan, doctors are seeing more strains that are resistant to ampicillin, a common antibiotic prescribed to treat salmonella. Multidrug resistance, or resistance to more than three classes of antibiotics, has also increased in Michigan and could further complicate patient treatment plans.

Were still uncertain as to why this is happening; it could be that these antibiotics have been overprescribed in human and veterinary medicine and that possessing genes for resistance has allowed these bacteria to grow and thrive in the presence of antibiotics, Manning said. Each state has its own antibiotic-resistance issues. Its important that the medical profession remains vigilant to ever-changing patterns of resistance in salmonella and other foodborne pathogens, rather than look for a blanket national solution.

Historically, salmonella has affected young children and the elderly, but now theres been a rise in adult cases, suggesting that the epidemiology of the infections has changed in Michigan.

Diving into individual strains of salmonella, the team of scientists found that patients with Typhimurium were more likely to have resistant infections as were patients infected during the fall, winter or spring months.

Another distinction was revealed between the strains affecting people living in rural and urban areas. Enteritis infections tend to be higher in rural areas. This may be attributed to rural residents exposure to farm animals or untreated sources of water.

Each states salmonella population has its own personality; so every states approach to identifying disease drivers and effective treatments should be modified to reflect these traits.

Our results show the importance of surveillance, monitoring resistance frequencies and identifying risk factors specific to each state and region, Manning said. The trends that are revealed can lead to new prevention strategies.

Additional MSU researchers contributing to the study include Sanjana Mukherjee, the lead author, Chase Anderson and Rebekah Mosci. Scientists from Wayne State, Sparrow Hospitals and the Michigan Department of Health and Human Services also contributed to this research.

(Note for media: Please include a link to the original paper in online coverage: https://www.frontiersin.org/articles/10.3389/fmed.2019.00250/full)

Here is the original post:

The nature of salmonella is changing and it's meaner - MSUToday

BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors – Yahoo Finance

Dr. Singh is renowned for her expertise in molecular science, clinical management and national health policy

RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that it has named Vanila M. Singh, M.D., MACM, to its Board of Directors.

Dr. Singh is currently a Clinical Associate Professor of Anesthesiology, Pain and Peri-operative Medicine at Stanford University School of Medicine and is a teaching mentor at Walter Reed National Military Medical Center. Dr. Singh is the immediate past Chief Medical Officer of the United States Department of Health and Human Services (HHS) and served as Chairperson of the Inter-Agency Pain Management Best Practices Task Force, chartered by Congress and involving multiple federal health agencies, professional medical organizations, and patient advocacy groups to guide the medical community and key stakeholders in optimal patient care in a growing and complex national health matter.

We are very excited and honored to have Dr. Singh join our organization as a Board member, stated Peter Greenleaf, Chairman of BDSI. Vanilas profound knowledge and experience in the fields of molecular science, clinical care, public health, and matters of national health policy will be wonderful complements to the significant depth of capabilities already on our Board and across the organization. Her passion and national recognition as an ambassador for optimal patient care blends perfectly with our companys patient centric culture and commitment to commercializing clinically differentiated products with meaningful therapeutic value.

Having spent my clinical career and policy-making leadership focused on improving clinical outcomes through best practices and patient-centered recommendations, I am proud to extend my vision by joining BDSIs Board and to further deliver solutions that address unmet patient care and focus on challenges that affect the healthcare system, added Dr. Singh.

Dr. Singh, board-certified in both anesthesiology and pain medicine, specializes in treating patients with complex chronic pain issues. She graduated from the University of California at Berkeley with a Bachelor of Science degree in both molecular and cell biology and economics. She received her Medical degree from the George Washington University School of Medicine & Health Sciences. Dr. Singh completed her internal medicine internship at Yale University School of Medicine and her anesthesiology residency and pain medicine fellowship at Weill-Cornell New York Presbyterian Hospital, which included training at Memorial Sloan Kettering and the Hospital for Special Surgery. She received a masters degree in academic medicine through the University of Southern Californias Keck School of Medicine in 2016. Dr. Singh has been active in various national medical organizations, having served in the past as the Vice Chair of the National Physicians Council on Health Policy; an editorial board member of the Pain Physician Journal for the American Society of Interventional Pain Physicians; and a member of the California Medical Associations (CMA) House of Delegates. She also served on the CMAs Council on Ethical, Legal and Judicial Affairs, and more recently, as a member of its Subcommittee on Health Information Technology, scientific planning committee of the American Society of Regional Anesthesia and Pain, and an active member of the American Society of Anesthesiology. In 2018 she was honored with a Lifetime Achievement Award by the American Society of Interventional Pain Physicians.

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence, and opioid-induced constipation.

Story continues

Cautionary Note on Forward-Looking Statements

This press release and any statements of employees, representatives, and partners of BDSI related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSIs plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential or similar expressions. These statements are based upon the current beliefs and expectations of the BDSIs management and are subject to significant risks and uncertainties, including those detailed in the BDSIs filings with the Securities and Exchange Commission. Actual results may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSIs control) including those set forth in our 2018 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

2019 BioDelivery Sciences International, Inc. All rights reserved.


Tirth T. PatelDirector of Investor Relationstpatel@bdsi.com(919) 582-0294

See original here:

BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors - Yahoo Finance

Could yoga, tai chi and mindfulness reduce the risk of inflammatory disease? – Epigram

By Jade Bruce, Second year, Cellular and Molecular Medicine

The benefits of activities such as yoga, tai chi and quigong may have farther-reaching impacts than we think.

Today, it is well known that psychological stress can have a physical impact, triggering or aggravating conditions such as diabetes and high blood pressure. Yet, the idea that the mind plays a role in physical illness and healing is not new. Recognition of this mind-body phenomenon dates back to Ancient Greek medicine which embraced the healthy mind, healthy body concept. Modern research now suggests that mind-body practices like yoga and tai chi can reduce the risk of inflammatory disease.

Inflammation is a vital part of the bodys response to harm and is characterised by heat, pain, redness, swelling, and loss of function. Acute inflammation is short term and plays a crucial role in protecting our bodies from infection and healing wounds. Without inflammation wed struggle to heal a cut or fight freshers flu when it inevitably hits. However, not all inflammation is protective. Chronic or abnormal inflammation can be harmful and has been linked to a range of diseases including cancer and Alzheimers disease.

| How sports can become the defining feature of your university experience

Research suggests that stress can trigger inflammation. Persistent social and academic pressures mean students tend to be all too familiar with stress, but stress isnt always an enemy; sometimes it can push us to work hard and prepare for challenges. Its when stress becomes chronic or severe that it can negatively impact mental health and increase the risk of developing an inflammation-related disease. But how exactly do our bodies translate this stress into inflammation?

Its all to do with a protein complex called NF-kB, which is key in controlling the expression of inflammatory genes. When we are stressed the sympathetic nervous system is stimulated to produce NF-kB, which then converts this stress into inflammation by switching on genes that code for inflammatory molecules, called cytokines. It follows that stress-reducing activities, which lower the activity of NF-kB, may not only improve mental health but reduce the risk of inflammatory disease as well.

One study looked at the effect of mindfulness in breast cancer survivor patients. After practicing two hours of yoga a week for a total of six weeks, participants showed lower levels of NF-kB and other inflammatory molecules. They reported decreased stress, fatigue and depression. Other studies have shown that activities ranging from mindfulness to Qigong can alleviate the symptoms of a variety of inflammatory diseases including irritable bowel disease as well as reducing blood pressure.

Taoist Tai Chi Society Awareness day, Millenium square Bristol Uk Yesterday pic.twitter.com/sEfeGBJCVO

The extent to which mind-body interventions reduce the risk of inflammatory-related diseases is uncertain, with some studies giving conflicting results. Indeed, its hard to tease apart the effect of activities like yoga from other important lifestyle interventions such as a balanced diet and exercise.

| My experience using healthcare apps

Scientists are continuing to explore the molecular changes which underpin the benefits of mind-body interventions and the role they have in inflammation. Nonetheless, studies have shown a clear overall pattern that mind-body therapies may reduce the risk of inflammatory disease. So, whether you feel the urge to take up Tai Chi or just want to dust off that yoga mat, it may well be worth it!

Featured image: Epigram / Vilhelmiina Haavisto

Do you practice mind-body activities? Let us know!

Excerpt from:

Could yoga, tai chi and mindfulness reduce the risk of inflammatory disease? - Epigram

Is the future of nuclear medicine, radiology heading in the right direction? Experts take a look – Health Imaging

Such an abundance of training pathways, in combination with often disjointed publicly available information regarding their differences, has been described as confusing for physicians and medical students alike, Yoo et al. explained.

Online information from (nuclear medicine and nuclear radiology) NM/NR websites may play a significant role in not only clarifying the dynamic changes in the field and its training pathways, but also in attracting prospective applicants to the discipline altogether, they added.

In order to understand workforce trends, the team looked at data from the 2017 American College of Radiology Commission on Human Resources Workforce Survey. They also reviewed board certification training pathway data and accredited nuclear medicine residency or nuclear radiology fellowship training websites to determine their comprehensiveness.

Over the last 10 years, the researchers noted, traditional training pathways for nuclear medicine and radiology programs have declined by 25%, while the number of trainees in the subspecialties has fallen by more than half.

See more here:

Is the future of nuclear medicine, radiology heading in the right direction? Experts take a look - Health Imaging

Novo Ventures and Broad Institute of MIT and Harvard Launch Drug Discovery Greenhouse to Drive Creation of Innovative New Therapies – BioSpace

BOSTON--(BUSINESS WIRE)-- Novo Ventures and the Broad Institute of MIT and Harvard announced today the launch of the Novo Broad Greenhouse, a joint initiative to discover and propel transformative new therapies from academic science into the clinic.

To drive the development of the next generation of molecular medicines, the Novo Broad Greenhouse unites three core ingredients: deep basic science expertise from academia, world class drug-discovery capabilities from the Broad Institutes Center for the Development of Therapeutics (CDoT), and a sustainable funding base and therapeutics development expertise from Novo Holdings.

The Novo Broad Greenhouse seeks to accelerate drug discovery projects led by members of the Broad Institute community, spanning institute faculty and professional scientists, including Broad-affiliated faculty at MIT, Harvard, and Harvard-affiliated hospitals.

Novo Holdings, through its US subsidiary, has committed up to $25 million over a five-year period to fund seed-stage drug discovery projects at Broad, spanning a wide range of indications and therapeutic modalities. Seed projects may include efforts to validate new drug targets, to assess how druggable certain proteins or genes are, or to develop new assays to assess the potential of drug candidates.

As projects progress beyond the seed phase, additional, separate funding is envisioned to fund the sprout phase of continued progress towards a clinical candidate, and ultimately the bloom phase -- graduation from the Greenhouse towards definitive clinical testing in patients, supported either by a new biotech company or by a strategic partner.

Novo Holdings investment approach and long-term view allow us to play a sustained role across all stages of drug development, from the earliest discoveries through to pivotal clinical testing, said Thomas Dyrberg, Managing Partner at Novo Holdings. We are thrilled to actively engage with the Boston academic research community in partnership with the Broad and believe this effort can help to catalyze the translation of exciting discoveries into new drug candidates.

The pace at which we can now discover the biological mechanisms and root causes of disease is staggering, said Todd Golub, Chief Scientific Officer of the Broad Institute and a member of the Greenhouses Joint Steering Committee. But in so many cases, these discoveries aren't yet making it past the lab. The Greenhouse gives us a new opportunity to collaborate across boundaries, combining our expertise with our partners to transform our knowledge into the therapies that will benefit patients.

Faculty and professional scientists at CDoT work closely together to translate curiosity-driven academic research into drug discovery projects. In its structure, partnerships, and capabilities, CDoT functions like a pharma or biotech. Most of the centers leadership comes from industry and has extensive drug discovery experience. CDoTs pipeline of projects incorporates multiple therapeutic areas, including cancer, cardiovascular, psychiatric diseases, and immunoregulation. Project stages span the drug discovery process from target validation to lead optimization.

The Novo Broad Greenhouse is one of several early-stage initiatives within Novo Holdings and exemplifies Novo Holdings interest to fund breakthrough science into new medicines. Novo Ventures is one of several investment teams employed by Novo affiliates that supports the investment activities of Novo Holdings, one of the worlds largest life science focused investment companies. Novo Ventures aims to facilitate the investment of approximately $500 million annually in private and public life science opportunities in the US, Europe, and Asia. Given Novo Holdings evergreen funding structure, multiple investment strategies, and global reach, Novo Holdings is uniquely positioned to invest in and support life science companies from inception through commercialization.

About Novo Holdings A/S and Novo Ventures Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundations assets.

Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.

For more information: http://www.novoholdings.dk/

Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings investments in private, public, and structured product opportunities in the life sciences industry.

For more information: https://www.novoholdings.dk/investments/ventures/

About Broad Institute of MIT and Harvard The Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.

The Center for the Development of Therapeutics (CDoT) is an organization of professional drug discovery scientists whose mission is to translate the biological insights developed at the Broad into therapeutics. CDoT is deeply embedded within the Broad Institute, but in its structure, capabilities, and leadership experience, CDoT closely resembles the drug discovery group of a pharma/biotech.

For more information: https://www.broadinstitute.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005186/en/

The rest is here:

Novo Ventures and Broad Institute of MIT and Harvard Launch Drug Discovery Greenhouse to Drive Creation of Innovative New Therapies - BioSpace

US scientists found PGRMC-2, a protein present in abundance in fat tissues with potential to manage… – Firstpost

What if someone told you that the fix for many problems linked with obesity could be hidden away, ironically, in rolls of fat in the body?

Scientists at Scripps Research, US, recently said just this. They have found PGRMC-2, a protein present in abundance in fat tissues, which has the potential to manage metabolic diseases like diabetes.

Representational image. AFP

Progesterone Receptor Membrane Component 2 or PGRMC-2 is a protein which acts as a chaperone to an essential molecule called heme. And guess where we have a bunch of heme in the body? Brown fat, also known as good fat, of course. But the Scripps team also found the protein in the liver, in sperm, and even inside the placenta.

Heme is an iron-containing molecule that helps in binding with oxygen thus carrying out crucial life processes such as cellular respiration, cell reproduction, cell death and circadian rhythms (24-hour cycle of the body). It also gives blood its red colour.

PGRMC-2 encapsulates the heme and guides it to travel from the cell's mitochondria, where heme is formed, to the nucleus, where it carries out its functions. Without PGRMC-2 as a protective chaperone, free heme acts as a toxin and causes oxidative stress and inflammation leading to cellular and tissue injury.

Enrique Saez, PhD, associate professor in the Department of Molecular Medicine at Scripps Research, along with his team did further research on PGRMC-2 to find out if it can be effective in reversing some of the serious health effects of obesity.

The research was done on mice who didnt have PGRMC-2 and who were fed a high-fat diet. In due time it became clear that in the absence of the protein PGRMC-2, the mices bodies started becoming glucose intolerant and insulin insensitive.

Glucose intolerance is a prediabetic stage in which the blood glucose levels are above normal but they are not high enough for you to be diagnosed as a diabetic. Normal fasting blood glucose levels are less than 100 mg/dl but if it comes anywhere between 100-125 mg/dl, it is considered to be a prediabetic state.

Insulin insensitivity refers to the inability of insulin to absorb glucose in the body, thus leading to high blood sugar levels. When the scientists treated these mice with a drug that activated the PGRMC-2 protein in their bodies, they noted a substantial improvement in their symptoms: the mice were less glucose intolerant and less resistant to insulin.

The scientists found that in the absence of the protein, the mices body could not generate body heat. The reason, in the absence of the protein, the scientists said, the good brown fat in mices bodies had started looking white! Brown fat is packed with iron-rich mitochondria which burn calories to produce heat in the body.

With this discovery, the scientists believed that activating the heme chaperone in other organs like the liver, which is a reservoir for heme, could help alleviate the effects of other metabolic disorders such as non-alcoholic steatohepatitis (NASH), which is one of the reasons why so many people need a liver transplant today.

Health articles in Firstpost are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health. For more information, please read our article on Liver Transplant: Who Needs It, and Why?

Here is the original post:

US scientists found PGRMC-2, a protein present in abundance in fat tissues with potential to manage... - Firstpost

Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief – PR Web

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says.

MILWAUKEE (PRWEB) November 25, 2019

The American Society of Gene & Cell Therapy (ASGCT) announced today the appointment of Roland W. Herzog, Ph.D. and Gerhard Bauer as editors-in-chief of the Societys field-leading journals, Molecular Therapy and Molecular TherapyMethods & Clinical Development, respectively. Both editors will begin their positions effective January 1, 2020.

Herzog, currently the editor-in-chief of Molecular TherapyMethods & Clinical Development, will assume the same role for a five-year term at Molecular Therapy from Seppo Yl-Herttuala, M.D., Ph.D. at the conclusion of Yl-Herttualas term. Herzog is also a professor of pediatrics, Riley Children's Foundation Professor of Immunology, and director of the gene and cell therapy program at Indiana University.

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says. My vision has continued and even further strengthened close coordination and collaboration between the journal editors and partnership with Cell Press and ASGCT.

Bauer replaces Herzog at the helm of Molecular TherapyMethods & Clinical Development after serving as an associate editor of the same journal for more than four years. Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures.

Over the years that I have been looking at manuscripts submitted to the journal, I have always loved the articles dealing with translational research, getting the products ready for clinical applications, improving their utility and solving problems in the manufacturing of these products, Bauer says. Now, at a time where we have clinical efficacy and also commercially approved cell and gene therapy products that save lives, it is even more important to strengthen the translational research field.

ASGCTs official journal, Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402.

The aim of Molecular TherapyMethods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular TherapyMethods & Clinical Development's 2018 impact factor is 4.875.

In addition to Molecular Therapy and Molecular Therapy Methods & Clinical Development, ASGCT also owns and operates two other sibling journals, Molecular TherapyNucleic Acids (2018 impact factor 5.919) and Molecular TherapyOncolytics (2018 impact factor 5.710).

About ASGCTThe American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email:

Read more:

Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief - PR Web

Find works by Nam June Paik at the UCSD Stuart Collection Art Walk – San Diego Reader

This walk continues exploring the many works of art commissioned by the Stuart Collection in partnership with the University of California, San Diego campus. Part 1 left off at the universitys Media Center, where works by artist Nam June Paik are found. As in the first part, each sculpture described below is numbered in the text next to the mileage.

Continuing the trek, walk past the Communications building and head north past the Thurgood Marshall College. At Sequoyah Hall, turn west and walk toward the grassy knoll where there are student apartments and five large blocks at mile 1.7 (11). Each block spells out UNDA (Latin for wave) by transposing the letters written on top of each block. Artist Ian Hamilton Finlay is relating to the velocity and flow of language. This sculpture is, appropriately, next to the Humanities building.

Retrace steps back to the Thurgood Marshall College. Because there is construction on campus and Scholars Drive North is closed, walk south past the construction and past Muir Lane and the Faculty Club. Turn right (west) toward Muir College and Stewart Commons, walking past the Patrick J. Ledden Auditorium. Just before reaching Johns Place & Market, look left to a large granite Green Table constructed by artist Jenny Holzer at mile 2.1 (12). The picnic or refectory table and benches are inscribed with various texts. This is a place for faculty and students to meet, and some of the politically charged texts create an opportunity for questioning and debate.

Retrace your steps back to the Faculty Club. On the right is a sculpture entitled Sun God by artist Niki de Saint Phalle, at mile 2.3 (13), in a large grassy area. Erected in 1983, this was the first sculpture commissioned by the Stewart Collection. One of the largest annual events on campus is the Sun God Festival, which began in 1984. The Sun God is a stunningly colorful 14-foot bird on top of a 15-foot concrete arch.

Next, walk a short distance northeast to find Robert Irwins Two Running Violet V Forms, also at mile 2.3 (14). You will walk beneath two blue-violet chain-link fence-like structures in a V-form. The artist plays with the manmade eucalyptus forest that was planted in an unnatural grid by introducing industrialized geometry that plays with the same light that is found in the grove.

From here, head right (south) on Mandeville Lane, cross Gilman Drive, and then head southwest along Gilman Drive to a service driveway on the left between the George Palade Laboratories for Cellular and Molecular Medicine and the Center for Neural Circuits and Behavior. Pass between the buildings to a grassy area and turn left. Cresting the small knoll, look down to see linear patterns of red, black, green-gray mosaic entitled Terrace by artist Jackie Ferrara at mile 2.7 (15). A series of terraces flowing into each other provides contemplative areas for the scientists who work in the buildings surrounding the terraces.

From the terraces, walk generally around the buildings back to Gilman Drive and go over the bridge to Revelle College and the main plaza. Turn right (north) to view a large pole with a beacon between Urey and Meyer Halls at mile 3.0 (16), entitled What Hath God Wrought by artist Mark Bradford. The pole marks the spot of the universitys founding plaque where a communication tower was to be placed, according to the original university design, but which never was. The structure celebrates the first communication by telegraph and Morse code.

From the pole, walk south to the lawn, south of Galbraith Hall, just before Scholars Drive to find La Jolla Project by artist Richard Fleischner at mile 3.2 (17). It has a Stonehenge-look to it that blends ancient and modern architecture. From here, use the crosswalk and walk west (right) along Scholars Drive, following a dirt path toward La Jolla Playhouse. Follow Revelle College Drive past the playhouse to a dirt path leading into a eucalyptus grove and The Wind Garden designed by John Luther Adams at mile 3.4 (18). As you enter the grove, listen to the musical notes that seem to emanate from the trees and change according to the wind. A bench has a plaque with a name of this landscape sculpture. It is an invitation to listen deeply to the music of this place.

Backtrack to a crosswalk over to another eucalyptus grove to the west where you will see a sign that advertises a trail that leads about 0.7 mile to the ocean. This is called the Ridge Walk Rain Garden, which is a water conservation garden that promotes watershed stewardship and offers an optional hike. If you choose to follow this trail, you will add about 1.5 miles to the trek, but be sure to come back to see the Red Shoe and pick up the remaining miles along the Stewart Collection. Go past the sign and take the path through the trees, looking to the left to see the large Red Shoe sculpture by artist Elizabeth Murray at mile 3.5 (19) that evokes a fairy tale or cartoon, inviting children to play and explore. Continue on the path and veer left to go over the footbridge, swinging right at the university entrance at Revelle College Drive from North Torrey Pines Road.

Then head to the left of the university entrance sign that reads Mandel Weiss Center. Cut through the vegetation heading toward North Torrey Pines Road. There is a faint use-trail that heads to the hillside. As you near the fence separating you from North Torrey Pines Road, look for log steps that climb up the hill along a nature trail that goes behind the La Jolla Playhouse. This short winding dirt trail through beautifully landscaped cultivars is a delight, with occasional seats to stop and contemplate the surrounding beauty of this garden area. The trail continues to loop around and along the backside of buildings until it comes to the final sculpture, which is a view of La Jollas suburban sprawl, at mile 3.7 (20), entitled La Jolla Vista View by artist William Wegman. The artist chose not to feature the scenic ocean view but rather a scenic look at urban development and construction sites to give the university community a fresh new critical look at its surroundings. Points of interest include housing and shopping developments. The site has a telescope and a metal plaque that identifies these key points of interests as of 1988, and viewers can see how development has continued to increase since then.

From the view site, follow Mandell Weiss Drive to its junction with Scholars Drive South, and continue to follow the road to Gilman Drive. Use the crosswalk and head right toward the Information Center to end the loop at about mile 4. Continue walking to your vehicle.

For more information about the Stuart Collection, see this website: stuartcollection.ucsd.edu.


Continue discovering unusual works of art by leading artists.

Driving directions: From I-5, take exit 28, La Jolla Village Drive west to Villa La Jolla Drive and turn south (left). Drive about 0.25 mile to La Jolla Village and turn left into the parking lot near Nordstrom Rack and park. Street parking on Gilman Drive is difficult to find. Vehicles can park for free for two hours in the shopping center. Hiking length: 4 miles from the trailhead, plus 1-mile roundtrip from the shopping center to the start point. 5 miles total. Difficulty: Easy walkways on campus and a short 0.1-mile dirt nature trail with log steps. Facilities available. Leashed, licensed dogs allowed on campus. NOTE: The route and sculpture descriptions are divided into two parts. This is Part 2, which covers the second set of 10 sculptures. See Part 1, which ran the previous week for a description of the first 10 sculptures.

View post:

Find works by Nam June Paik at the UCSD Stuart Collection Art Walk - San Diego Reader

Meet the Researcher: Riqiang Yan, Neuroscience – UConn Today

When he first entered college, Riqiang Yan wanted to be a doctor. But he soon changed paths when he realized how exciting the research tract was.

When I had just graduated high school, I was kind of nave. I didnt know much about the field until I came to college and became more fascinated by the research, Yan says. I wanted to make knowledge in the science part.

Yan began doing research during his undergraduate thesis project, which was trying to develop a new drug formulation for ulcer treatment at Shanghai Medical University. He was so interested in the project that he continued working on it even after his graduated, which was very unusual at that time for a student who otherwise could have enjoyed time off during the summer break. Yan credits Prof. Yuanming Ma () with providing him that opportunity, and guided him toward the research career path he eventually followed. Following this experience, Yan received his masters degree in biochemistry at Shanghai Medical University and went on to earn his Ph.D. in biochemistry at the University of Kentucky.

Yan is now one of the worlds leading Alzheimers disease researchers. He is a professor and chairman of UConn Healths Department of Neuroscience, leading discovery efforts at UConns School of Medicine. Yan came to UConn from the Cleveland Clinic in 2018. He established the first research program focused on studying Alzheimers and other forms of neurodegenerative disease in hopes of potentially discovering effective treatments.

Yans arrival at UConn also ushered in a host of research collaboration opportunities across the School of Medicine and its departments of neurology, neurosurgery, psychiatry, neurobiology, the Center on Aging, and brain investigators at the University, as well as with the Jackson Laboratory for Genomic Medicine on UConn Healths campus.

Cutting-Edge Alzheimers Research

Now a preeminent scholar in the field, Yan didnt start out doing Alzheimers research. At the beginning of his independent research career, Yan was studying inflammation in lung diseases for global pharmaceutical company Pharmacia & Upjohn. When the companys priorities changed, Yan shifted over to Alzheimers research. The neurodegenerative disease that affects an estimated 5.5 million Americans has no known cure.

I ended up in Alzheimers research by accident, Yan says. It was a very exciting time because we had so many unknown questions about Alzheimers disease to explore.

That accident turned out to be extremely productive. One year after making the switch, Yan made a breakthrough discovery.

In 1999, Yan and several other groups of researchers simultaneously discovered that an enzyme known as BACE1 plays a crucial role in the processes that lead to the onset of Alzheimers disease. BACE1 cleaves amyloid precursor proteins which give rise to beta amyloid. This peptide is the main component of plaques on brain cells, one of the culprits for causing Alzheimers disease.

From there, researchers from multiple pharmaceutical and biotech companies began developing trials of BACE1 inhibitors in hopes of stopping the effects of BACE1s activity. However, all these trials failed. While these failures were frustrating, they taught scientists an important lesson about this key enzyme; not only does BACE1 activity lead to Alzheimers disease, it is also responsible for ensuring parts of normal neural activity. By blocking it completely, the treatments did more harm than good.

Things Are Not So Simple

We still dont have a drug, Yan says, 20 years after the original discovery. These early trials with BACE1 failed because if you simply inhibit it, it interferes with necessary brain functioning. Its challenging.

Yan reflects that this is one of the most challenging aspects of his research. The human body is not simple, and neither are the diseases that afflict it. Before we can develop an effective treatment for Alzheimers disease, we need to understand how it works at a basic molecular level.

Many times, you will find out things are not so simple, Yan says. We need to understand the biology before we can have an effective drug.

Most recently, Yan published a paper in the Journal of Experimental Medicine about the role of CX3CL1, a transmembrane protein, on Alzheimers disease. Yan found that CX3CL1 is cleaved by BACE1. He also found that an overexpression of the C-terminal fragment of CX3CL1 can reduce amyloid deposition and neuron loss in mice with Alzheimers disease. This is the first time its been shown that the C-terminal CX3CL1 can aid adult neurogenesis which directly combats the neurodegeneration of Alzheimers disease.

This development of knowledge underscores the role of academic researchers in eventual drug discovery, Yan says. Developing knowledge about diseases and the workings of the human body is the foundation for future drugs.

Were in academia. Our main focus is to understand the molecule first before we try to develop a compound, Yan says.

If researchers or pharmaceutical companies go into drug trials without this critical understanding, they could encounter many harmful side effects. With a better understanding of the science behind the disease, such side effects could be better anticipated and even avoided.

Yan says researchers can help pharmaceutical companies develop more effective drugs by working in tandem with industry partners.

We may not be able to compete with the pharmaceutical companies directly in some cases, but we can do something to help the companies develop better drugs, Yan says. And thats whats more important to us.

Follow UConn Research on Twitter & LinkedIn.

Read more:

Meet the Researcher: Riqiang Yan, Neuroscience - UConn Today

NantHealth (NASDAQ:NH) Stock Price Up 2.6% – Riverton Roll

NantHealth Inc (NASDAQ:NH)s stock price rose 2.6% on Monday . The stock traded as high as $1.17 and last traded at $1.20, approximately 1,600 shares changed hands during mid-day trading. A decline of 99% from the average daily volume of 170,258 shares. The stock had previously closed at $1.17.

NH has been the topic of several analyst reports. ValuEngine raised shares of NantHealth from a sell rating to a hold rating in a report on Tuesday, November 19th. Cowen set a $1.00 target price on shares of NantHealth and gave the company a buy rating in a report on Monday, August 26th. Finally, Zacks Investment Research downgraded shares of NantHealth from a buy rating to a hold rating in a report on Thursday, August 15th.

The firm has a market cap of $118.36 million, a PE ratio of -0.69 and a beta of 1.21. The companys fifty day moving average price is $0.76 and its two-hundred day moving average price is $0.64.

NantHealth (NASDAQ:NH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by ($0.08). NantHealth had a negative net margin of 105.82% and a negative return on equity of 10,106.10%. The company had revenue of $22.36 million during the quarter, compared to analyst estimates of $23.40 million. As a group, equities analysts predict that NantHealth Inc will post -0.46 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in NH. Paloma Partners Management Co lifted its stake in shares of NantHealth by 436.1% in the second quarter. Paloma Partners Management Co now owns 91,100 shares of the companys stock valued at $48,000 after purchasing an additional 74,108 shares during the period. Miracle Mile Advisors LLC lifted its stake in shares of NantHealth by 154.2% in the second quarter. Miracle Mile Advisors LLC now owns 75,000 shares of the companys stock valued at $39,000 after purchasing an additional 45,500 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of NantHealth by 778.8% in the third quarter. Tower Research Capital LLC TRC now owns 45,988 shares of the companys stock valued at $33,000 after purchasing an additional 40,755 shares during the period. Hedge funds and other institutional investors own 3.27% of the companys stock.

About NantHealth (NASDAQ:NH)

NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.

Featured Article: Options Trading Understanding Strike Price

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.


NantHealth (NASDAQ:NH) Stock Price Up 2.6% - Riverton Roll